415 related articles for article (PubMed ID: 12479700)
1. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
2. The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti D; Vergani V; Drudis T; Borsotti P; Pitelli MR; Viale G; Giavazzi R; Taraboletti G
Clin Cancer Res; 1996 Nov; 2(11):1843-9. PubMed ID: 9816139
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Grant DS; Williams TL; Zahaczewsky M; Dicker AP
Int J Cancer; 2003 Mar; 104(1):121-9. PubMed ID: 12532428
[TBL] [Abstract][Full Text] [Related]
4. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere).
Lu H; Murtagh J; Schwartz EL
Mol Pharmacol; 2006 Apr; 69(4):1207-15. PubMed ID: 16415178
[TBL] [Abstract][Full Text] [Related]
5. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Rosenblum MD; Shivers RR
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Jan; 125(1):121-31. PubMed ID: 11790336
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Kelland LR; Abel G
Cancer Chemother Pharmacol; 1992; 30(6):444-50. PubMed ID: 1356649
[TBL] [Abstract][Full Text] [Related]
7. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
8. Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation.
Murtagh J; Lu H; Schwartz EL
Cancer Res; 2006 Aug; 66(16):8192-9. PubMed ID: 16912198
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.
Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M
Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340
[TBL] [Abstract][Full Text] [Related]
12. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells.
Farinelle S; Malonne H; Chaboteaux C; Decaestecker C; Dedecker R; Gras T; Darro F; Fontaine J; Atassi G; Kiss R
J Pharmacol Toxicol Methods; 2000; 43(1):15-24. PubMed ID: 11091126
[TBL] [Abstract][Full Text] [Related]
13. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells.
Lefranc F; Mijatovic T; Mathieu V; Rorive S; Decaestecker C; Debeir O; Brotchi J; Van Ham P; Salmon I; Kiss R
Clin Cancer Res; 2004 Dec; 10(24):8250-65. PubMed ID: 15623601
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of inhibition of endothelial cell migration by taxanes.
Kamath K; Smiyun G; Wilson L; Jordan MA
Cytoskeleton (Hoboken); 2014 Jan; 71(1):46-60. PubMed ID: 24155271
[TBL] [Abstract][Full Text] [Related]
15. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
17. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
18. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
Avramis IA; Kwock R; Avramis VI
Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283
[TBL] [Abstract][Full Text] [Related]
19. Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain.
Andreu JM; Díaz JF; Gil R; de Pereda JM; García de Lacoba M; Peyrot V; Briand C; Towns-Andrews E; Bordas J
J Biol Chem; 1994 Dec; 269(50):31785-92. PubMed ID: 7989352
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
